Dr. Parsyan Chosen as Outstanding Author
Dr. Parsyan was selected as one of the 2025 Outstanding Authors by Translational Cancer Research for his research article, "Investigation of effects of CFI-400945 and ionizing radiation on DNA damage response in triple-negative breast cancer", Athwal et al, Transl Cancer Res 2025 Jun 30;14(6):3822-3832. This research was the culmination of work done in large part by our former MSc student, Harjot K Athwal and represents years of work looking into the synergistic effect of using the anti-cancer drug, CFI-400945, in combination with radiation treatment to enhance anti-tumour effects.
The designation of Outstanding Author is given to those authors who, according to TCR, "... make outstanding contributions to our journal.... have received very (good) feedback in the field and stimulate a lot of discussions and new insights among the peers.... authors who have been making immense efforts in their research fields".
TCR recently interviewed Dr. Parsyan regarding his perspective on cancer research, academic writing and the importance of a collaborative mindset in scientific discovery. According to Dr. Parsyan, "...finding a coveted cure for cancers is not a one-person effort but rather a product of combined input from clinicians, scientists, patients, and many others". He likens the scientific search for cancer's vulnerablities as "the target we want to strike and .... strike it effectively". He continues, "... (to do that), requires vast research efforts and can only be achieved through a forum where all researchers share bits and pieces of new knowledge to assemble the Lego of the target....academic writing provides that forum". One can read the interview in its entirety on the TCR website, Outstanding Author interviews.
